434 related articles for article (PubMed ID: 27803005)
1. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Lee SH; Lee JK; Ahn MJ; Kim DW; Sun JM; Keam B; Kim TM; Heo DS; Ahn JS; Choi YL; Min HS; Jeon YK; Park K
Ann Oncol; 2017 Feb; 28(2):292-297. PubMed ID: 27803005
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Matsumoto S; Kohno T; Tsuta K; Tsuchihara K; Ishii G; Nomura S; Sato A; Ohtsu A; Ohe Y; Goto K
Lancet Respir Med; 2017 Jan; 5(1):42-50. PubMed ID: 27825616
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Platt A; Morten J; Ji Q; Elvin P; Womack C; Su X; Donald E; Gray N; Read J; Bigley G; Blockley L; Cresswell C; Dale A; Davies A; Zhang T; Fan S; Fu H; Gladwin A; Harrod G; Stevens J; Williams V; Ye Q; Zheng L; de Boer R; Herbst RS; Lee JS; Vasselli J
BMC Cancer; 2015 Mar; 15():171. PubMed ID: 25881079
[TBL] [Abstract][Full Text] [Related]
4. Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Yoh K; Seto T; Satouchi M; Nishio M; Yamamoto N; Murakami H; Nogami N; Nosaki K; Kohno T; Tsuta K; Nomura S; Ikeno T; Wakabayashi M; Sato A; Matsumoto S; Goto K
Lung Cancer; 2021 May; 155():40-45. PubMed ID: 33725547
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
[TBL] [Abstract][Full Text] [Related]
6. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Natale RB; Bodkin D; Govindan R; Sleckman BG; Rizvi NA; Capó A; Germonpré P; Eberhardt WE; Stockman PK; Kennedy SJ; Ranson M
J Clin Oncol; 2009 May; 27(15):2523-9. PubMed ID: 19332730
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
[TBL] [Abstract][Full Text] [Related]
8. Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Dagogo-Jack I; Stevens SE; Lin JJ; Nagy R; Ferris L; Shaw AT; Gainor JF
J Thorac Oncol; 2018 Nov; 13(11):e226-e227. PubMed ID: 30368414
[No Abstract] [Full Text] [Related]
9. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Tsao AS; Liu S; Lee JJ; Alden CM; Blumenschein GR; Herbst R; Davis SE; Kim E; Lippman S; Heymach J; Tran H; Tang X; Wistuba I; Hong WK
J Thorac Oncol; 2013 May; 8(5):658-61. PubMed ID: 23584298
[TBL] [Abstract][Full Text] [Related]
10. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Natale RB; Thongprasert S; Greco FA; Thomas M; Tsai CM; Sunpaweravong P; Ferry D; Mulatero C; Whorf R; Thompson J; Barlesi F; Langmuir P; Gogov S; Rowbottom JA; Goss GD
J Clin Oncol; 2011 Mar; 29(8):1059-66. PubMed ID: 21282542
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Morabito A; Piccirillo MC; Costanzo R; Sandomenico C; Carillio G; Daniele G; Giordano P; Bryce J; Carotenuto P; La Rocca A; Di Maio M; Normanno N; Rocco G; Perrone F
Drugs Today (Barc); 2010 Sep; 46(9):683-98. PubMed ID: 20967300
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang X; Qin Y; Li H; Bai C; Zhu T; Xu J; Wu C; Wu M; Wang C; Song H; Wei L; He J
Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
[TBL] [Abstract][Full Text] [Related]
16. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
Ahn JS; Lee KH; Sun JM; Park K; Kang ES; Cho EK; Lee DH; Kim SW; Lee GW; Kang JH; Lee JS; Lee JW; Ahn MJ
Lung Cancer; 2013 Dec; 82(3):455-60. PubMed ID: 24075125
[TBL] [Abstract][Full Text] [Related]
17. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
Lung; 2011 Dec; 189(6):437-43. PubMed ID: 21986852
[TBL] [Abstract][Full Text] [Related]
18. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Leboulleux S; Bastholt L; Krause T; de la Fouchardiere C; Tennvall J; Awada A; Gómez JM; Bonichon F; Leenhardt L; Soufflet C; Licour M; Schlumberger MJ
Lancet Oncol; 2012 Sep; 13(9):897-905. PubMed ID: 22898678
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
Xiao YY; Zhan P; Yuan DM; Liu HB; Lv TF; Shi Y; Song Y
Clin Oncol (R Coll Radiol); 2013 Jan; 25(1):e7-e15. PubMed ID: 23177099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
